Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|118|4|590-597

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.118, Iss.4, 2016-10, pp. : 590-597

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

By  

Oncology, Vol. 90, Iss. 2, 2016-0 ,pp. : 69-78

Karger

Access to resources Recommend Favorite

High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

By  

Urologia Internationalis, Vol. 90, Iss. 1, 2012-11 ,pp. : 56-61

Karger

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

By  

THE PROSTATE, Vol. 75, Iss. 8, 2015-06 ,pp. : 836-844

John Wiley & Sons Inc

Access to resources Recommend Favorite